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It has been twenty years since the ﬁrst paper reporting the association between thyroid antibodies (TAIs) and spontaneous
miscarriage was published. Following this observation, several studies have clearly demonstrated an increased prevalence of TAI in
patients with recurrent miscarriage (RM). However, the exact mechanism underlying this association remains a matter of debate.
The aim of the present study was to evaluate the thyroid function, throughout a speciﬁc test, in patient with RM and TAI focusing
on the hypothesis that TAI should be an indirect sign of a mild thyroid dysfunction. 46 patients with RM and TAI were included in
the study. All patients underwent short TRH stimulation test showing an abnormal response in the vast majority of cases (65%).
Normal FT4 and FT3 mean values were found whereas TSH values were in the upper normal range (2.64 ± 1.3mUI/L). Our data
supportthehypothesisthatinpatientswithRMthepresenceofTAIisanindirectsignofasubtlethyroiddysfunctiondetectableby
a speciﬁc test. This test give the possibility to identify women with RM in which speciﬁc therapeutic approaches could eﬀectively
improve the possibility for a successful pregnancy.
1.Introduction
During the last decade much work has been done in the
area of thyroid and pregnancy, and signiﬁcant advances in
the understanding of thyroid function modiﬁcations have
been reached. A general agreement has developed in the
potential relationship between diﬀerent pregnancy patholo-
gies, such as abortion, gestational hypertension, and dia-
betes, and even subclinical thyroid disorders such as subclin-
ical hypothyroidism and the presence of thyroid antibodies
(TAI) [1]. In particular, a great amount of observations have
clearly established that the presence of TAI is associated with
a signiﬁcant increased miscarriage risk [2]. Furthermore, it
has been demonstrated that the prevalence of TAI in patients
with recurrent miscarriage (RM) is higher with respect to
that found in normal fertile control suggesting that TAI
shouldbeconsideredasanindependentindicationoftherisk
of pregnancy loss [3, 4]. Nevertheless, the exact mechanism
underlying the association between TAI and miscarriage
remains a matter of debate, and a clear explanation for this
phenomenon has not been clearly established. Eﬀectively,
two possibilities for this association can be considered: im-
mune dysfunction or mild thyroid abnormalities. Some
authors suggest that the most plausible hypothesis is that
women with thyroid autoantibodies have an underlying,
more generalized autoimmune activity, which leads to in-
creased fetal losses [5, 6]. If this explanation is true, then it
would be reasonable to think that the best therapy would
require the modulation of the immune function. Neverthe-
less, to date, no studies have demonstrated the eﬃcacy of
these therapies in preventing miscarriage in patients with
TAI. In addition, our previous study has demonstrated that2 International Journal of Endocrinology
treatment with high-dose immunoglobulin, a therapy which
can inﬂuence the immune system, does not signiﬁcantly im-
prove the obstetric prognosis in patients with unexplained
RM and TAI [7]. In fact, in agreement with other authors,
we hypothesise that in women exhibiting TAI the thyroid is
less able to adapt to the increased requirements of pregnancy
leading to an inadequate thyroid hormones release [8]. From
this point of view, it is plausible that the increased mis-
carriage rate in patients with TAI could be due to a thyroid
dysfunction, rather than a generalized overreaction of the
immunesystem.Theaimofthepresentstudywastoevaluate
the role thyroid autoantibodies in patients with RM focusing
on the study of thyroid function throughout a speciﬁc test.
2.MaterialandMethods
2.1. Patients. From January 2001 to January 2010, six hun-
dred and thirty patients with a history of RM attended the
outpatient Clinic of the University of Rome “Tor Vergata”.
Among these patients 46 were prospectively included in the
study. Clinical inclusion criteria included the presence of 2
or more ﬁrst trimester consecutive abortions. Laboratory
criteria required the presence of TAI (antithyroperoxidase
and/or antithyroglobulin antibodies). Patients with chronic
diseases, with chronic ongoing treatments, or oral contra-
ception were excluded from the study. Thyroid function tests
included FT4, FT3, and basal and TRH-stimulated serum
TSH (assessed 20min after the TRH bolus). Clinical features
of patients are summarized in Table 1.
2.2. Methods. A standard short TRH test was performed in
early follicular phase in addition to routine hormonal checks
by giving 200mcgr TRH (TRH BIOCHEM, Ferring Gmbh,
Berlin,Germany)intravenouslyandmeasuringtheTSHlevel
at 0 and 20 minutes after bolus. In all studied subjects, TRH
test was performed at the 7th/8th day of the menstrual cycle
after an overnight fasting at 8 AM.
Serum TSH, FT3, and FT4 were measured using a super-
sensitive electrochemiluminescence immunoassay (Roche,
Mannheim, Germany). Thyroperoxidase antibody and thy-
roglobulin antibodies were evaluated by means of an elec-
trochemiluminescence immunoassay (Roche, Mannheim,
Germany). Thyroperoxidase antibody and thyroglobulin an-
tibodies were considered positive when values exceeded
65IU/mL for TPO-Ab and 115UI/mL for TG-Ab. According
to previous studies, impaired response was deﬁned when
TSH TRH-stimulated level was higher than 15mUI/mL 20
minutes after the bolus [9].
3. Results
As reported in Figure 1, the vast majority of patients showed
an abnormal TRH-stimulated TSH response. In fact, 30 out
of 46 patients (65%) showed a TSH TRH-stimulated level
higher than 15mUI/mL 20 minutes after the bolus with a
mean TSH values of 17.8±8.1mUI/L. However, as shown in
Table 1, the mean FT3 and FT4 levelswerewithin thenormal







Basal TSH 20 minutes after TRH bolus
Figure 1: Mean basal (green) and TRH-stimulated TSH (blue)
values (mUI/mL) in patients with RM and TAI.
Table 1: Clinical features of patients.
Mean age (years) 35.9 ±5
Mean abortions’ number 2.5±0.8
Mean abortion week 7.5±1.7
Mean FT3 values (mUI/L) 3.3±1.2
Mean FT4 values 4.7±5.1
Mean TSH values 2.6±1.8
the upper part of the normal range. It has note worthily been
established that a TSH value below 2.5mUI/L is advisable in
women wishing to conceive [10, 11]. Finally, all patients had
normal thyroglobulin serum concentrations.
4. Discussion
The present study supports the hypothesis that patients with
RM and TAI are characterized by a subtle thyroid dysfunc-
tion that worsening during early pregnancy can lead to an
inadequate thyroid hormones release. In particular, our data
demonstrated that in these patients conventional laboratory
tests could not reveal this abnormality. In fact, normal FT3,
FT4, and TSH levels were found in most of the patients
with mean levels within the normal range. Interestingly, an
abnormal response to short TRH stimulation test was found
in the vast majority of our patients (65%). From our point
of view, this test represents an important tool for the study
of thyroid function in patients with RM. In this test basal
and TRH-stimulated serum TSH (assessed 20min after the
TRH bolus) are evaluated. Patients with abnormal TRH-
stimulated TSH response could be considered to have an
impaired thyroid function [9]. Therefore, we suppose that
this exam may represent a sensible test to identify patients
in which the thyroid function is less able to adapt to the
increased requirement of pregnancy even in presence of
normal peripheral thyroid hormones’ concentrations [12].
This hypothesis is supported by a research showing that
women with unsuccessful pregnancy, at the time of abortion,
displayed high basal and TRH-stimulated TSH levels, withInternational Journal of Endocrinology 3
normal T4 serum concentrations, higher when compared to
those observed among women with normal pregnancy [9].
Accordingly, in our previous study, we have shown that, in
patientswithRMandimpairedresponsetoTRHtest,thyroid
replacement therapy can signiﬁcantly improve reproductive
outcome [7]. Therefore, the high incidence of an impaired
TRH test among patients with RM and TAI supports the
hypothesis that these patients are characterized by a reduced
functional thyroid reserve leading to an inadequate con-
centrations of thyroid hormones necessary for successful
pregnancy. As extensively reported, thyroid hormones have
a crucial role in all phases of pregnancy. In the early stage
of gestation, these hormones can inﬂuence the trophoblast
endocrine function through direct stimulatory eﬀects on the
production and secretion of progesterone, estradiol, hGC
(α and β), and placental lactogen [13–15]. Therefore, an
inadequate thyroid hormone availability at the trophoblasts
levelcanleadtoanabnormaltrophoblastendocrinefunction
[13–15]. Moreover, diﬀerent studies suggest a possible role
of thyroid hormones in regulating apoptosis at throphoblast
level. In particular, it has been shown that thyroid hormones
suppress apoptosis downregulating the expression of Fas and
Fas ligand in early placental extravillous trophoblast [16].
In addition the importance of an adequate concentration of
thyroidhormoneforanormalplacentationprocessisfurther
supported by “in vitro” evidence demonstrating that thyroid
can inﬂuence the invasiveness and the diﬀerentiation of cul-
tured extravillous trophoblast cells hormones upregulating
the expression of integrins and metalloproteases [17].
Later in pregnancy an impaired thyroid function has
been associated with potential repercussions aﬀecting the
oﬀspring. Recent evidence has suggested that even mild
thyroid underfunction may be associated with an impaired
fetal brain development. In fact, lower IQ scores have been
demonstrated in children whose mothers had hypothy-
roidism during pregnancy in comparison with children with
normal maternal thyroid function [18]. Moreover, it has
been reported that children of pregnant women with normal
thyroid function but increased thyroid peroxidase antibodies
are at risk for impaired psychomotor development [19].
Therefore, our data supporting the hypothesis that the
presence of TAI identiﬁes women at risk to develop fetal and
maternal complications suggesting that, in these patients, a
therapy which can reestablish thyroid homeostasis could be
essentialforasuccessfulpregnancy[7,8].Accordingly,inour
previous study we have demonstrated that the use of thyroid
replacement therapy, in patients with unexplained RM and
TAI, was found to be successful in reducing miscarriages.
In fact, this therapy resulted in 79% of the pregnancies
ending in full-term live births, which represents a signiﬁcant
improvement upon their obstetric prognosis without treat-
ment [7]. In addition, the high rate of successful pregnancy
observed in the study could be due to the appropriate time
of treatment initiation. In fact, the treatment was started
almost one month before pregnancy in order to obtain
the optimal thyroid hormone levels necessary to a normal
placental development. A more recent study has conﬁrmed
the eﬃcacy of thyroid replacement therapy in preventing
miscarriage and obstetrics complications in patients with
RMandTAI[8].Inthisstudymiscarriageratewascompared
between thyroid peroxidase antibody positive women who
were given levothyroxine beginning in the ﬁrst trimester of
pregnancy to euthyroid thyroid antibody positive women
who were not given levothyroxine (the control group). A
statistically signiﬁcant decrease in spontaneous miscarriage
was seen in treated women as compared to the controls.
In conclusion, our data further support the hypothesis
that in patients with RM the presence of TAI is associated
with a subtle thyroid dysfunction that can be detected by
speciﬁctest.Infact,thevastmajorityofourpatientswithRM
and TAI showed an abnormal response to TRH stimulation
tests. Therefore, the evaluation of thyroid autoimmunity and
the study of thyroid functioning, through TRH stimulation
tests, could be considered a useful tool for patients with a
historyofRM.Althoughlargerstudiesareneeded,ourresults
suggest that these tests could identify a group of patients
in which an appropriate therapy can eﬀectively increase the
possibility of a successful pregnancy.
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